Cargando…
Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment
BACKGROUND: Primary tumor location (PTL) is an important prognostic and predictive factor in the first-line treatment of metastatic colorectal cancer (mCRC). Although regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) have been introduced recently, the clinical impact of PTL in these treatments...
Autores principales: | Nakajima, Hiromichi, Fukuoka, Shota, Masuishi, Toshiki, Takashima, Atsuo, Kumekawa, Yosuke, Kajiwara, Takeshi, Yamazaki, Kentaro, Negoro, Yuji, Komoda, Masato, Makiyama, Akitaka, Denda, Tadamichi, Hatachi, Yukimasa, Suto, Takeshi, Sugimoto, Naotoshi, Enomoto, Masanobu, Ishikawa, Toshiaki, Kashiwada, Tomomi, Ando, Koji, Yuki, Satoshi, Okuyama, Hiroyuki, Kusaba, Hitoshi, Sakai, Daisuke, Okamoto, Koichi, Tamura, Takao, Yamashita, Kimihiro, Gosho, Masahiko, Moriwaki, Toshikazu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239287/ https://www.ncbi.nlm.nih.gov/pubmed/34211856 http://dx.doi.org/10.3389/fonc.2021.688709 |
Ejemplares similares
-
Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS)
por: Chida, Keigo, et al.
Publicado: (2021) -
Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study
por: Moriwaki, Toshikazu, et al.
Publicado: (2017) -
Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study
por: Shiroyama, Mamiko, et al.
Publicado: (2023) -
Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan
por: Ogata, Misato, et al.
Publicado: (2020) -
Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study
por: Chida, Keigo, et al.
Publicado: (2021)